Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
暂无分享,去创建一个
Satoshi Inoue | Antonello Mai | G. Cohen | S. Inoue | M. Dyer | A. Mai | Gerald M Cohen | Martin J S Dyer
[1] L. Altucci,et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells , 2005, Nature Medicine.
[2] P. Richardson,et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. , 2001, Blood.
[3] S. Kern,et al. A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. , 2000, Cancer research.
[4] Stuart L Schreiber,et al. Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. , 2002, Chemistry & biology.
[5] M. Grever,et al. The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells , 2004, Leukemia.
[6] J. Blenis,et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. , 2000, Immunity.
[7] S. Inoue,et al. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies , 2004, Cell Death and Differentiation.
[8] S. Grant,et al. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. , 2003, Molecular cancer therapeutics.
[9] J. Neuzil,et al. Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation. , 2004, Biochemical and biophysical research communications.
[10] W. El-Deiry,et al. Cell surface Death Receptor signaling in normal and cancer cells. , 2003, Seminars in cancer biology.
[11] Ping Zhu,et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells , 2001, The EMBO journal.
[12] S. Horinouchi,et al. In vivo destabilization of dynamic microtubules by HDAC6‐mediated deacetylation , 2002, The EMBO journal.
[13] Xiao-Fan Wang,et al. HDAC6 is a microtubule-associated deacetylase , 2002, Nature.
[14] K. Glaser,et al. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. , 2003, Biochemical and biophysical research communications.
[15] Ricardo Macarron,et al. Identification of Novel Isoform-Selective Inhibitors within Class I Histone Deacetylases , 2003, Journal of Pharmacology and Experimental Therapeutics.
[16] G. Cohen,et al. Fas-associated Death Domain Protein and Caspase-8 Are Not Recruited to the Tumor Necrosis Factor Receptor 1 Signaling Complex during Tumor Necrosis Factor-induced Apoptosis* , 2003, Journal of Biological Chemistry.
[17] Ricky W. Johnstone,et al. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer , 2002, Nature Reviews Drug Discovery.
[18] Minoru Yoshida,et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. , 2005, Molecular cell.
[19] S. Grant,et al. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. , 2003, Cancer research.
[20] G. Cohen,et al. Death receptors leave a caspase footprint that Smacs of XIAP , 2003, Cell Death and Differentiation.
[21] James Bradner,et al. Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90 , 2005, Journal of Biological Chemistry.
[22] S. Grant,et al. Histone deacetylase inhibitors: insights into mechanisms of lethality , 2005, Expert opinion on therapeutic targets.
[23] M. Yoshida,et al. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[24] P. Marks,et al. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. , 1999, Cancer research.
[25] T. Tsuruo,et al. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. , 2001, Cancer research.
[26] G. Cohen,et al. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia , 2002, Oncogene.
[27] S. Srinivasula,et al. Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL* , 1997, The Journal of Biological Chemistry.
[28] A. V. van Kuilenburg,et al. Histone deacetylases (HDACs): characterization of the classical HDAC family. , 2003, The Biochemical journal.
[29] A. Ashkenazi,et al. Targeting death and decoy receptors of the tumour-necrosis factor superfamily , 2002, Nature Reviews Cancer.
[30] D. Steensma,et al. On the TRAIL of a new therapy for leukemia , 2005, Leukemia.
[31] G. Cohen,et al. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1 , 2005, Cell Death and Differentiation.
[32] R. Maestro,et al. Role of Caspases, Bid, and p53 in the Apoptotic Response Triggered by Histone Deacetylase Inhibitors Trichostatin-A (TSA) and Suberoylanilide Hydroxamic Acid (SAHA)* , 2003, Journal of Biological Chemistry.
[33] Minoru Yoshida,et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. , 2002, Cancer research.
[34] E. Seto,et al. Activation of the Growth-Differentiation Factor 11 Gene by the Histone Deacetylase (HDAC) Inhibitor Trichostatin A and Repression by HDAC3 , 2004, Molecular and Cellular Biology.
[35] G. Cohen,et al. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. , 2005, Cancer research.
[36] Silvio Massa,et al. Histone deacetylation in epigenetics: An attractive target for anticancer therapy , 2005, Medicinal research reviews.
[37] A. Mai,et al. Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A. , 2003, Journal of medicinal chemistry.
[38] T. Griffith,et al. Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[39] P. Marks,et al. Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.
[40] L. Altucci,et al. Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. , 2005, Journal of medicinal chemistry.
[41] M. Peter,et al. Cytotoxicity‐dependent APO‐1 (Fas/CD95)‐associated proteins form a death‐inducing signaling complex (DISC) with the receptor. , 1995, The EMBO journal.
[42] Yahong Lin,et al. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. , 2002, Genes & development.
[43] D. Bernhard,et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[44] M. Butterworth,et al. Bcl-2 and Bcl-xL Inhibit CD95-mediated Apoptosis by Preventing Mitochondrial Release of Smac/DIABLO and Subsequent Inactivation of X-linked Inhibitor-of-Apoptosis Protein* , 2002, The Journal of Biological Chemistry.
[45] K. Shiraki,et al. Histone deacetylase inhibitors sensitize human colonic adenocarcinoma cell lines to TNF-related apoptosis inducing ligand-mediated apoptosis. , 2002, International journal of molecular medicine.
[46] M. Andreeff,et al. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL‐R1 and TRAIL‐R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin‐ and bortezomib‐induced cell death , 2005, British journal of haematology.
[47] P. Atadja,et al. Cotreatment with Histone Deacetylase Inhibitor LAQ824 Enhances Apo-2L/Tumor Necrosis Factor-Related Apoptosis Inducing Ligand-Induced Death Inducing Signaling Complex Activity and Apoptosis of Human Acute Leukemia Cells , 2004, Cancer Research.
[48] S. Kyrylenko,et al. Differential regulation of the Sir2 histone deacetylase gene family by inhibitors of class I and II histone deacetylases , 2003, Cellular and Molecular Life Sciences CMLS.
[49] J. Tschopp,et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8 , 2000, Nature Cell Biology.